Gene-Tailored drugs aim to tackle tough bile duct cancer
NCT ID NCT07164703
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether targeted drugs or immunotherapies, chosen based on a patient's specific gene mutations, can shrink tumors and extend life in advanced cholangiocarcinoma (bile duct cancer). About 55 adults with unresectable, advanced disease and a targetable gene mutation will receive personalized treatment. The goal is to see if this precision approach improves response rates and survival compared to standard care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Targeted drugs or immunotherapies based on gene mutations
What this could lead to
If successful, this could show that matching treatments to specific gene mutations improves outcomes for people with advanced cholangiocarcinoma.
What could go wrong
This is an early, real-world study with only 55 participants, so results may not apply broadly. The treatments may not work for all mutation types and could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CHOLANGIOCARCINOMA (PART 1) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Provincial Hospital of Fuzhou University
Fuzhou, Fujian, 350001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.